Q2 2018 13F Holders as of 6/30/2018
-
Type / Class
-
Equity / COM
-
Number of holders
-
160
-
Total shares
-
20.7M
-
Shares change
-
+1.17M
-
Total reported value, excl. options
-
$1.74B
-
Value change
-
+$107M
-
Put/Call ratio
-
0.61
-
Number of buys
-
87
-
Number of sells
-
-58
-
Price
-
$83.91
Significant Holders of INTERCEPT PHARMACEUTICALS IN - COM (ICPT) as of Q2 2018
179 filings reported holding ICPT - INTERCEPT PHARMACEUTICALS IN - COM as of Q2 2018.
INTERCEPT PHARMACEUTICALS IN - COM (ICPT) has 160 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 20.7M shares
.
Largest 10 shareholders include FMR LLC (4.44M shares), BlackRock Inc. (2.03M shares), VANGUARD GROUP INC (1.9M shares), STATE STREET CORP (1.33M shares), JPMORGAN CHASE & CO (1.27M shares), Senvest Management, LLC (976K shares), FIRST TRUST ADVISORS LP (841K shares), Sarissa Capital Management LP (635K shares), CITADEL ADVISORS LLC (613K shares), and BB BIOTECH AG (546K shares).
This table shows the top 160 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.